#Hypertension remains the leading modifiable risk factor for #CVD, despite decades of therapeutic efforts. Aldosterone dysregulation is increasingly recognized as a missing piece of the puzzle. Read: https://t.co/azEq90Cemp $MLYS

Our team was in #Detroit w/ @blackgirlsrun & Dr. John Flack who discussed health equity & how black women can prioritize healthy living. Mineralys is focused on improving outcomes for people w/ #hypertension, including high-risk populations, & was honored to be part of this event

We will be presenting lorundrostat data from our Phase 2 Explore-CKD trial in a late-breaking session next month at @ASNKidney #KidneyWk on Friday, November 7. Read our press release for additional details: https://t.co/cWSIQ3ejFl #Hypertension #CKD #ClinicalData $MLYS

Our CEO spoke with @statnews about recent breakthroughs in understanding cardiovascular diseases and how targeting aldosterone could reshape #hypertension treatment. Read the Q&A here: https://t.co/azEq90CMbX #HighBloodPressure #CardioRenalMetabolic $MLYS

Today we announced completion of enrollment in Explore-OSA, our Ph 2 #clinicaltrial examining the efficacy, safety & tolerability of lorundrostat in participants with #OSA and #hypertension. Topline results anticipated in Q1 2026. Learn more here: https://t.co/0lntOStQ9C $MLYS

Hypertension or high blood pressure affects 1.4B people globally. It’s the most prevalent & modifiable risk factor of cardiovascular diseases. In the U.S., 70M+ people aged 30–79 years have uncontrolled #hypertension. #WorldHeartDay #HighBloodPressure ❤️

New WHO report finds 1.4 billion people live with #hypertension. Hypertension is the number one risk factor for: ‼️ Heart attack ‼️ Stroke and can lead to: ‼️ Chronic kidney disease ‼️ Dementia Get your blood pressure checked today! Learn more 👉 https://t.co/rO4S68pJ6r

In just 6 years, Mineralys advanced #lorundrostat, a potential first-in-class aldosterone synthase inhibitor, from concept to pivotal published trials in #hypertension and is now preparing for a pre-NDA meeting in Q4 2025. Learn more: https://t.co/XuS9z9odi2 #Innovation $MLYS

𝐇𝐂𝐖 𝟐𝟎𝟐𝟓: @Mineralystx's CEO John Congleton describes the rational of targeting aldosterone for hypertension and discusses his company's pivotal data. $MLYS Full video: https://t.co/ok2bEpVA0p

Our CEO spoke with @ThePharmaLetter about Mineralys’ clarity of purpose, long-term vision, & the clinical opportunities for lorundrostat to treat #hypertension and other aldosterone-driven conditions. #CardiovascularDisease #CardioRenalMetabolic $MLYS

Dr. Manish Saxena is presenting new subgroup analyses from our Launch-HTN trial of lorundrostat at the American Heart Association Hypertension Scientific Sessions. Details: https://t.co/67HgFApzEo #Hypertension25 #BloodPressure $MLYS

Today we closed the sale of additional stock shares in our underwritten public offering, bringing total gross proceeds to $287.5M. Funds will support clinical development of lorundrostat, R&D and manufacturing, & pre-commercial activities. Read: https://t.co/zGgDcWL7Mu $MLYS

Today we reported financial results for the second quarter ending June 30, 2025, and provided a corporate update. Learn more: https://t.co/ahNHwtxXPj #Hypertension #CKD #OSA #CardioRenalMetabolic #CVRM $MLYS

We will report our financial results from the second quarter ended June 30, 2025, after the financial markets close on Tuesday, August 12, 2025. Register for the conference call here: https://t.co/IHasvUdeVm #Hypertension $MLYS

Detailed results from the pivotal P3 Launch-HTN trial were published today in @JAMA_current, reinforcing lorundrostat’s efficacy in a real-world setting. Read our press release to learn more: https://t.co/nxVKImi8Nw #bloodpressure $MLYS

Today we announced positive topline results from our Phase 2 Explore-CKD trial evaluating the safety & efficacy of lorundrostat in subjects with #hypertension and comorbid chronic kidney disease (CKD). Read more https://t.co/IE68t1JuTu $MLYS #bloodpressure #chronickidneydisease

Today we presented detailed results from our pivotal Ph3 Launch-HTN trial at #ESH2025, reinforcing the promise of lorundrostat as a new treatment approach for aldosterone driven #hypertension. Read our press release to learn more: https://t.co/Ly02MqNU7B $MLYS #bloodpressure

We will be sharing data from our pivotal Phase 3 Launch-HTN trial in a late-breaking session at #ESH2025 on Saturday, May 24 from 10:00-11:00am CEST. Read our press release for additional details: https://t.co/kV3ux6jmLG $MLYS #hypertension #bloodpressure

Today we reported financial results for the first quarter ending March 31, 2025, and provided a corporate update. Learn more: https://t.co/t3EO9MeYAV $MLYS #Hypertension #CardioRenalMetabolic

We will report our financial results from the first quarter ended March 31, 2025, after the financial markets close on Monday, May 12, 2025. Register here: https://t.co/1010o1903h